David Apelian, Eiger BioPharmaceuticals CEO
September 13, 2023 06:53 AM EDTUpdated 11:17 AM
R&D

Eiger ends PhI­II he­pati­tis delta tri­al over safe­ty con­cerns — and the search for treat­ment part­ner

Katherine Lewin

News Reporter

Eiger Bio­Phar­ma­ceu­ti­cals is end­ing a Phase III tri­al in­ves­ti­gat­ing its treat­ment in liv­er in­fec­tions caused by the he­pati­tis D virus over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times